PMC2879548_01
Gottron's sing on the dorsal surface of the proximal interphalangeal joint. Erythematous areas at the bases of the fingernails are seen.
IJOL2010-401825.001.jpg
PMC2879548_01_IJOL2010-401825.001.jpg
fig1
For 1 month, the patient had noticed a systemic rash, the typical heliotrope coloration of the upper eyelids, Gottron's sign on the dorsal surface of his proximal interphalangeal joints, erythematous areas at the bases of the fingernails (Figure 1), dysphagia, and proximal muscle weakness of both extremities, but he and his family did not think that the symptoms were serious.
Case 1: Clinical Course. Treatment and serum CK levels are shown. CP: cyclophosphamide.
IJOL2010-401825.002.jpg
PMC2879548_01_IJOL2010-401825.002.jpg
fig2
The patient's clinical course is shown in Figure 2.
PMC2879548_02
Case 2: Clinical Course. Treatment and serum CK levels are shown.
IJOL2010-401825.003.jpg
PMC2879548_02_IJOL2010-401825.003.jpg
fig3
Figure 3. Five months after treatment was finished, positron emission tomography/computed tomography (PET-CT) showed no residual tumor so no neck dissections were carried out.
PET-CT. (a) Pre-treatment. Intense FDG uptake is detected in the left cervical region and the nasopharynx. Mild FDG uptake is detected in the muscles of the entire body, especially the upper extremities. (b) Post-treatment. FDG uptake with residual tumor is not detected. FDG uptake in the muscles is improved compared to pre-treatment.
IJOL2010-401825.004.jpg
PMC2879548_02_IJOL2010-401825.004.jpg
fig4
Pre- and posttreatment PET-CT scans are shown in Figure 4.